2021 U.S. Industry Statistics & Market Research - Research & Development in the Physical, Engineering & Life Sciences

Published: January 2021

Product & Services Breakdown

Research products and services in the Research & Development in the Physical, Engineering & Life Sciences industry generating sales. Note that products are broken into categories with different levels of classification.

Product Description	Number of Companies	Sales ($ millions)	Percent of Total Sales
Industry Total
Basic And Applied Research In The Physical And Engineering Sciences
Basic And Applied Research In - Chemistry And Chemical Engineering
Basic And Applied Research In - Computer, Electrical, And Electronic Engineering
Basic And Applied Research In - Earth And Environmental Sciences
Basic And Applied Research In - Material, Mechanical, And Industrial Engineering
Basic And Applied Research In - Physics
Basic And Applied Research In - Astronomy
Basic And Applied Research In - Other Physical Sciences, Including Math, And Other Natural And Exact Sciences (Exclude Biologica
Basic And Applied Research In - Other Engineering Sciences, Including Civil, Construction, And Other Engineering
Computer Systems Design, Development, And Integration Services
Testing Services (Physical Or Product), Excluding Medical And Veterinary Services
Basic And Applied Research In Biotechnology
Basic And Applied Research In The Life Sciences (Exclude Biotechnology.)
Basic And Applied Research In - Pharmacology And Pharmaceutical Sciences
Basic And Applied Research In - Medical And Health Sciences
Basic And Applied Research In - Biological Science
Basic And Applied Research In - Agriculture, Forestry, And Allied Sciences
Basic And Applied Research In - Animal Production, Fisheries, And Veterinary Sciences
Basic And Applied Research In - Other Life Sciences, Excluding Biotechnology
Basic And Applied Research In The Social Sciences And Humanities
Basic And Applied Research In - Education
Development Services For Goods
Development Services For Service Products Processes, Systems, Or Methods
Outright Sale Of Original Works Of Intellectual Property
Advisory And Consulting Services For Research And Development Activities
Engineering Services
Licensing Of Rights To Use Intellectual Property
Licensing Of Rights To Use Intellectual Property Protected By Copyright
Licensing Of Rights To Use Intellectual Property Protected As Industrial Property
Resale Of Merchandise
All Other Receipts
All Other Operating Receipts
Contributions, Gifts, And Grants - Government
Contributions, Gifts, And Grants - Private
Investment Income, Including Interest And Dividends
All Other Revenue

U.S. Geographic Distribution: Revenue Statistics by State

Market Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.

Income Statement (Average Financial Metrics)

Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.

	Industry Average	Percent of Sales (Industry Benchmark)
Total Revenue	Order at top of page
Operating Revenue
Cost of Goods Sold
Gross Profit
Operating Expenses
Pension, profit sharing plans, stock, annuity
Repairs
Rent paid on business property
Charitable Contributions
Depletion
Domestic production activities deduction
Advertising
Compensation of officers
Salaries and wages
Employee benefit programs
Taxes and Licenses
Bad Debts
Depreciation
Amortization
Other Operating Expenses
Total Operating Expenses
Operating Income
Non-Operating Income
EBIT (Earnings Before Interest and Taxes)
Interest Expense
Earnings Before Taxes
Income Tax
Net Profit Net Income

Source: AnythingResearch Analysis of U.S. federal statistics

Compensation & Salary Surveys for Employees

Compensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.

Title	Percent of Workforce	Bottom Quartile	Average (Median) Salary	Upper Quartile
Management Occupations	14%	Order at top of page
Chief Executives	0%
General and Operations Managers	2%
Other Management Occupations	6%
Business and Financial Operations Occupations	10%
Business Operations Specialists	8%
Computer and Mathematical Occupations	12%
Computer Occupations	11%
Software Developers and Programmers	5%
Architecture and Engineering Occupations	17%
Engineers	14%
Life, Physical, and Social Science Occupations	25%
Life Scientists	12%
Medical Scientists	7%
Medical Scientists, Except Epidemiologists	7%
Life, Physical, and Social Science Technicians	7%
Office and Administrative Support Occupations	9%

Source: Bureau of Labor Statistics

Research & Development in the Physical, Engineering & Life Sciences Competitor Landscape & Key Companies [PREMIUM]

The most influential companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent sectors:

Market Leaders: Direct Competitors Companies with the largest market share, focused in this industry	Market leaders: Diversified Competitors Largest companies that have diversified operations in this and other industries
Innovators: Direct Competitors Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry.	Innovators: Diversified Competitors Innovators and Disruptors in adjacent industries that may also affect the Research & Development in the Physical, Engineering & Life Sciences industry.

Executive Briefings

We are engaged in segments of the pharmaceutical industry that are highly competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are commercializing or pursuing the development of products that target HCV, RSV, HBV, NASH, hMPV and SARS-CoV-2 and other viral infections or liver diseases that we may target in the future. Many of our competitors have substantially greater commercial infrastructures and financial, technical and personnel resources than we have, as well as drug candidates in late-stage clinical development. We will not be able to compete successfully unless we are able to:   • design and develop products that are superior to other products in the market;   • attract qualified scientific, medical, regulatory, sales and marketing and commercial personnel;   • obtain patent and/or other proprietary protection for our processes and product candidates;   • obtain required regulatory approvals; or   • collaborate with others in the development and commercialization of new products. Established competitors may invest heavily to quickly discover and develop novel compounds that could make our product candidates obsolete. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety, or some combination of these factors, to overcome competition and to be commercially successful. We expect AbbVie’s MAVYRET/MAVIRET to continue to face intense competition due to existing approved products in the HCV market. AbbVie’s HCV treatment regimens currently face competition in various world markets and subpopulations of HCV from Gilead’s Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a triple combination therapy of sofosbuvir, velpatasvir and voxilaprevir approved by the FDA in July 2017 for specified sofosbuvir -treatment failures and NS5A-inhibitor treatment failures) and Harvoni® (a fixed-dose combination of sofosbuvir and ledipasvir); and to a lesser extent - Merck’s Zepatier® (a fixed-dose combination of grazoprevir and elbasvir). Gilead launched authorized generic versions of Epclusa and Harvoni in January 2019 through a newly created subsidiary, Asegua Therapeutics, LLC, which has had an impact on the competitive landscape. Other competitive products in the form of other treatment methods or a vaccine for HCV may render AbbVie’s HCV regimens obsolete or noncompetitive. AbbVie’s regimens that contain one of our collaboration’s protease inhibitors will face competition based on their safety and effectiveness, reimbursement coverage, price, patent position, AbbVie’s marketing and sales capabilities, and other factors. If any of AbbVie’s HCV regimens face competition from generic products other than authorized generic versions by the manufacturer of the branded product (i.e. If AbbVie is not able to compete effectively against its competitors in HCV, our business will not grow and our financial condition, operations and stock price will suffer. 16   We also expect our other product candidates to face intense and increasing competition in the NASH and antiviral markets as advanced technologies and products become available. Though there is currently no approved treatment for NASH, we expect significant competition from other companies in the development of new treatments for NASH and related conditions. In February 2019, Intercept Pharmaceuticals announced positive Phase 3 trial results for OCA (brand name Ocaliva®) in NASH and submitted U.S. We are aware of several other companies with NASH programs that are significantly more advanced than ours, including companies with compounds in Phase 3 clinical trials in NASH, namely AbbVie, Galmed, Intercept, and Madrigal. In addition, a number of companies have NASH or related programs with compounds in Phase 2 clinical trials. These companies include 89bio, Afimmune, Akcea, Akero, AngioLab, AstraZeneca, BMS, Can-Fite BioPharma, Cirius, Cymabay, Eli Lilly and Company, Enyo, Galectin, Gilead, HighTide Biopharma, Immuron, Inventiva, Kowa Company, Lipocine, Medicinova, Metacrine, Mitsubishi Tanabe Pharma, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, NuSirt Biopharma, Pfizer, Poxel SA, PharmaKing, Sagimet Biosciences, TaiwanJ Pharmaceuticals, Terns, Theratechnologies, Viking Therapeutics, and Zydus. A significant number of other companies are conducting earlier stage clinical trials that may be applicable in NASH. There are also additional companies conducting preclinical studies in these disease areas. Similarly, HBV and RSV represent competitive therapeutic areas. Many companies are seeking to develop new HBV drugs that alone or in combination with other mechanisms could lead to a functional cure of HBV. Assembly, Gilead, GSK/Ionis, HEC, Johnson Enanta Pharmaceuticals

Government Contracts

In 2020, the federal government spent a total of $331,844,138,177 on Research & Development in the Physical, Engineering & Life Sciences. It has awarded 12589 contracts to 3386 companies, with an average value of $98,004,766 per company.   

Most Recent Contracts	Date	Total Award Amount